TOX3 and breast carcinoma: To determine if de-methylation of the promoter could increase expression of TOX3, we treated a basal-like breast cancer cell line (UACC-3199) with a DNA methylation inhibitor, 5-aza-2’-deoxycytidine (5-aza-CdR).